Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IVIb

Small molecule · Inhibitor · developed by Cumberland Pharmaceuticals

Phase 1 Most advanced trial (none active)

CPIX Developer

1 Registered trials

What is IVIb?

IVIb is an investigational small-molecule drug studied in Healthy.

At a glance

Drug type: Small molecule
Mechanism: Inhibitor
Developer: Cumberland Pharmaceuticals (CPIX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT00867880	Phase 1	Healthy	Completed	CPIX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy

More from Cumberland Pharmaceuticals

Ifetroban Phase 2

Sources

ClinicalTrials.gov NCT00867880

Updated Oct 3, 2026. Something wrong or missing? Report it on the CPIX page.

Follow CPIX, the company behind IVIb

See CPIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CPIX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z